Biotech

All Articles

Lilly experiences period 2 breakdown of tau-targeting med

.The confetti is actually still flying coming from Eli Lilly's party commemorating the commendation ...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of substantial leadership hirings, shootings ...

Lykos are going to inquire FDA to reevaluate its selection observing rejection of MDMA therapy for trauma

.Adhering to a bad presenting for Lykos Therapies' MDMA applicant for post-traumatic stress disorder...

AN 2 halves roll call, stops phase 3 test after data let down

.AN2 Therapeutics is reviewing its company in response to poor midphase data, swearing to lay off ha...

Merck pays $700M for bispecific, snooping autoimmune position as well as opportunity to test Amgen in cancer

.Merck &amp Co. is spending $700 thousand ahead of time to challenge Amgen in a blood cancer market....

Gilead pays for J&ampJ $320M to exit licensing offer for seladelpar

.With Gilead Sciences almost an FDA choice for its liver health condition medicine seladelpar, the c...

' All hands on deck' at Lilly as peers target being overweight market

.Chief executive officer David Ricks can easily find the business establishing outdoors tents at bas...

Entero laying off team, vacating office and also pausing R&ampD

.Mattress Liquidators has switched Entero Rehabs white as a slab. The financial institution got Ente...

Exelixis drops ADC after determining it is actually no suit for Tivdak

.Exelixis is giving up on its tissue variable (TF)- targeting antibody-drug conjugate after wrapping...

Relay loses interest in SHP2 inhibitor after Genentech leaves behind

.Three full weeks after Roche's Genentech unit walked away from an SHP2 inhibitor deal, Relay Therap...